CUV 0.67% $14.72 clinuvel pharmaceuticals limited

positive news, page-3

  1. 648 Posts.
    It's fabulous news. Nothing is guaranteed in the biosphere and positive trial results are the best news we could get.

    In the unlikely event that that EPP final phase III results disapoint (which is very unlikely), the company has other solid results for the other indications. And having the orphan status for SU is another big plus.

    Hopefully good Phase II PDT results and good interim Phase III PLE results are soon to follow. Both are overdue.

 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$14.72
Change
-0.100(0.67%)
Mkt cap ! $737.1M
Open High Low Value Volume
$14.80 $14.97 $14.60 $600.3K 40.64K

Buyers (Bids)

No. Vol. Price($)
2 324 $14.69
 

Sellers (Offers)

Price($) Vol. No.
$14.75 100 1
View Market Depth
Last trade - 16.10pm 06/09/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.